medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 4

<< Back Next >>

Ann Hepatol 2004; 3 (4)

Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C

Soza A, Arrese M, González R, Alvarez M, Pérez RM, Cortés P, Patillo A, Riquelme A, Glasinovic JC

Language: English
References: 25
Page: 146-151
PDF size: 57.33 Kb.


Text Extraction

Prevalence, modes of transmission, clinical characteristics and outcomes of hepatitis C (HCV) infection vary in different geographical areas. We aim to describe clinical and epidemiological features of Chilean patients infected with hepatitis C virus. An analysis of demographic, epidemiological, clinical and laboratory data of patients referred to a liver clinic and blood donors with chronic hepatitis C was carried out. 147 patients were evaluated, 68 (46%) were male. Median age was 56 years, median infection age was 27 years and median duration of infection was 27 years. 52.5% of the patients were cirrhotic, and estimated risk of progression to cirrhosis was 16% at 20 years from infection. Risk factors for acquisition of the disease among patients were: Blood transfusion 54%, injection drug use 5%, and risky sexual behavior 2%. No factor was identified in 43% of the patients. Twelve of 64 (18.8%) family members tested positive for HCV antibodies. Genotype 1b was predominant (82%), and 52% of patients had high viral load (›850.000 IU/mL). Liver biopsy was available in 50 patients, showing advanced fibrosis in 54%. These patients were in average 10 years older and tended to have longer duration of infection. Hepatocellular carcinoma was present at the moment of enrollment in 7 patients and developed in 4 more patients during follow up (2.4 years). In conclusion, the natural history and clinical characteristics of HCV infection in Chilean patients is similar to that described elsewhere. The main risk factor was blood transfusion. A significant proportion of patients had advanced liver disease or hepatocellular carcinoma at time of diagnosis.


REFERENCES

  1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.

  2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  3. Armas-Merino R, Wolff C, Soto R, Jiron MI, Parraguez A. [Hepatitis C virus and resulting diseases]. Rev Med Chil 1999; 127: 1240-1254.

  4. Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D. Risk for transfusion-transmitted infectious diseases in Central and South America. Emerg Infect Dis 1998; 4: 5-11.

  5. Ministerio de Salud. Chile. Situación de la Hepatitis B, D y C en Chile, 1997. http://epi.minsal.cl/epi/html/public/hepat/situacionhepatitisbc.htm 1997.

  6. Muñoz G, Velasco M, Thiers V, Hurtado C, Brahm J, Larrondo-Lillo M, Guglielmetti A, et al. [Prevalence and genotypes of hepatitis C virus in blood donors and in patients with chronic liver disease and hepatocarcinoma in a Chilean population]. Rev Med Chil 1998; 126: 1035-1042.

  7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.

  8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.

  9. Velasco M, Hurtado C, Brahm J. [Anti-hepatitis C viral antibodies in different pathological entities in Chile]. Rev Med Chil 1990; 118: 895-896.

  10. Rodriguez MI, Estay R, Soto JR, Wolff C, Plubins L, Child R, Armas R. [Prevalence of hepatitis C virus antibodies in a hemodialysis unit]. Rev Med Chil 1993; 121: 152-155.

  11. Vega I, Leon A, Zolezzi P, Ibarra H, Faundez C, Montecinos J. [Hepatitis C virus in a group of hematological and oncohematological patients]. Rev Med Chil 2001; 129: 18-22.

  12. Ibarra H, Riedemann S, Siegel F, Toledo C, Reinhardt G. [Acute hepatitis caused by virus A, E and non A-E in Chilean adults]. Rev Med Chil 2001; 129: 523-530.

  13. Velasco M, Brahm J, Katz R. [Long term follow-up of patients with chronic hepatitis due to hepatitis C virus]. Rev Med Chil 1994; 122: 1271-1275.

  14. Vega I, Colina R, Garcia L, Uriarte R, Mogdasy C, Cristina J. Diversification of hepatitis C viruses in South America reveals a novel genetic lineage. Arch Virol 2001; 146: 1623-1629.

  15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.

  16. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 485-490.

  17. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.

  18. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695.

  19. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91-96.

  20. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233.

  21. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-870.

  22. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-587.

  23. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.

  24. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.

  25. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.




2020     |     www.medigraphic.com